{"filings":[{"id":556485,"accession_number":"0001193125-26-232786","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-05-20T20:59:48+00:00","items":["5.07"],"status":"ready","headline":"Amgen annual meeting elects all 12 directors; shareholder independent-chair proposal rejected","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Robert Bradway received 390M votes for, 20.5M against.","Advisory vote to approve executive compensation passed with 399M for, 12M against.","Ernst & Young ratified as auditor for FY2026 with 447M for, 28M against.","Stockholder proposal to require independent board chairman failed: 72.9M for, 338.5M against.","Broker non-votes of 63.7M on all items except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526797,"accession_number":"0000318154-26-000097","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-05-19T20:08:12+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen CFO Peter Griffith retiring; Thomas Dittrich to succeed September 1, 2026","event_type":"leadership","confidence":"high","bullets":["Peter Griffith retiring as EVP/CFO effective Aug 31, 2026; stays as non-executive EVP through Jan 2027.","Thomas Dittrich appointed EVP/CFO effective Sep 1, 2026; returns to Amgen after CFO roles at Galderma, Shire, Sulzer.","Dittrich receives CHF 1.07M base salary, CHF 4.5M LTI target, one-time RSU of CHF 4.7M and cash bonus of CHF 4M.","Dittrich to relocate from Switzerland to Thousand Oaks; receives relocation allowance of CHF 250K and standard severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97950,"accession_number":"0000318154-26-000054","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q1 2026 revenue $8.6B (+6% YoY), Non-GAAP EPS $5.15 (+5% YoY)","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.6B (+6% YoY); product sales grew 4% driven by 9% volume growth.","GAAP EPS $3.34 (+4% YoY); Non-GAAP EPS $5.15 (+5% YoY).","GAAP operating income $2.7B, margin 32.4% (up 17.4pp); Non-GAAP operating income $3.7B, margin 45.3% (down 0.4pp).","Free cash flow $1.5B in Q1 2026 vs $1.0B in Q1 2025.","16 products achieved double-digit sales growth in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":8618000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97949,"accession_number":"0000318154-26-000048","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amgen EVP and CTO David M. Reese to retire June 30, 2026; roles redistributed","event_type":"leadership","confidence":"high","bullets":["David M. Reese retires as EVP and CTO effective June 30, 2026; responsibilities split among Bradner, Gordon, Griffith starting June 1.","James Bradner becomes EVP of R&D, AI and Data; Sean Bruich named SVP and CTO.","Murdo Gordon takes EVP of Amgen Global Markets and Policy; Paul Burton remains Chief Medical Officer.","Reese joined Amgen in 2005, led R&D from 2018-2023, and served as inaugural CTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113165,"accession_number":"0001193125-26-059490","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amgen issues $4.0B in senior notes across four tranches with maturities 2031-2056","event_type":"debt","confidence":"high","bullets":["Issued $1.0B 4.200% notes due 2031, $1.75B 4.850% notes due 2036, $500M 5.500% notes due 2046, $750M 5.650% notes due 2056.","Net proceeds of ~$3.96B after underwriting discounts and estimated offering expenses.","Interest payable semi-annually on Feb 19 and Aug 19, starting Aug 19, 2026.","Holders may require repurchase at 101% upon a change-in-control triggering event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113164,"accession_number":"0000318154-26-000003","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.","GAAP EPS $2.45 Q4 (+111%), full year $14.23 (+88%); non-GAAP EPS full year $21.84 (+10%).","Recorded $1.2B Otezla intangible impairment due to IRA Medicare price setting.","Free cash flow $8.1B full year vs $10.4B prior, down on working capital timing.","18 products achieved record full-year sales; 14 exceeded $1B in annual sales."],"consensus_eps_estimate":null,"consensus_eps_actual":14.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":36751000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113163,"accession_number":"0001193125-26-030518","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance","event_type":"other_material","confidence":"high","bullets":["Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).","Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.","Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.","If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.","Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129560,"accession_number":"0000318154-25-000070","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64","event_type":"earnings","confidence":"high","bullets":["Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.","GAAP EPS $5.93 (+14% YoY), includes $400M Otezla intangible asset impairment charge.","Non-GAAP EPS $5.64 (+1% YoY); non-GAAP operating margin 47.1%, down 2.5 ppt.","Free cash flow $4.2B vs $3.3B in Q3 2024, driven by working capital timing and lower interest.","Sixteen products delivered double-digit sales growth including Repatha, EVENITY, TEZSPIRE, and BLINCYTO."],"consensus_eps_estimate":null,"consensus_eps_actual":11.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":26885000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146131,"accession_number":"0000318154-25-000054","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)","event_type":"earnings","confidence":"high","bullets":["Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.","GAAP EPS $2.65 vs $1.38 (+92%); GAAP operating income $2.7B, margin 30.3%.","Non-GAAP EPS $6.02 vs $4.97 (+21%); non-GAAP operating margin 48.9%.","Free cash flow $1.9B in Q2, down from $2.2B, reflecting deferred 2024 tax payments and higher capex.","Fifteen products had double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, TAVNEOS."],"consensus_eps_estimate":null,"consensus_eps_actual":5.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":17328000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164444,"accession_number":"0000950170-25-077233","cik":318154,"company_name":"AMGEN INC","ticker":"AMGN","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amgen shareholders elect all 12 director nominees and approve say-on-pay at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["All 12 directors elected; CEO Robert A. Bradway received 375.7M for (93.0%) vs 26.4M against.","Advisory say-on-pay approved with 381.3M for (93.1%) and 21.4M against.","Ernst & Young ratified as independent auditor for FY2025 with 441.6M for (94.1%) vs 26.7M against.","Broker non-votes on director elections and say-on-pay were 64.6M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}